Allergan plc (NYSE: AGN), based in Dublin, Ireland, is a global pharmaceutical company and one of the leading companies in the new "Growth Pharma" industry model. Allergan focuses on the development, production and marketing of pharmaceutical brands, medical devices and biologicals - for patients all over the world.

Allergan markets a portfolio of leading branded products and successful preparations in the areas of the central nervous system (CNS), ophthalmology, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infectives. In the area of ​​research and development, Allergan follows the model of "open science" in order to recognize and further develop groundbreaking ideas and innovations and thus achieve better patient care. With this approach, the company was able to develop one of the broadest development pipelines in the pharmaceutical industry with over 65 programs in the medium to late development stage.

Allergan has more than 18,000 employees worldwide and offices in nearly 100 countries. The company is committed to working with doctors, healthcare providers and patients to provide innovative and meaningful care to people around the world, enabling them to live a healthier and longer life.